ResMed Inc.
RMDNYSEHealthcare● Active
$193.86
$-2.18(-1.11%)
Market Cap$28.1B
P/E Ratio—
52W High$293.81
52W Low$180.27
ResMed Inc. (RMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RMD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$2.86
Est. $2.80 · +2.1%
Revenue
$1.43B
Est. $1.42B · +0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
RMD reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $2.90 | — | — | — | $1.47B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $2.80 | $2.86 | +2.1% | $1.43B | $1.42B | +0.8% |
| ▲ Q1 FY2026 | Jan 29, 2026 | $2.74 | $2.81 | +2.5% | $1.42B | $1.40B | +1.6% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $2.51 | $2.55 | +1.6% | $1.34B | $1.33B | +0.2% |
| — Q3 FY2025 | Jul 31, 2025 | $2.55 | $2.55 | +0.0% | $1.35B | $1.35B | +0.0% |
| — Q2 FY2025 | Apr 23, 2025 | $2.38 | $2.37 | -0.4% | $1.29B | $1.29B | +0.3% |
| ▲ Q1 FY2025 | Jan 30, 2025 | $2.32 | $2.43 | +4.7% | $1.28B | $1.27B | +1.2% |
| ▲ Q4 FY2024 | Oct 24, 2024 | $2.04 | $2.20 | +7.8% | $1.22B | $1.19B | +3.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$2.90
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$2.86
EPS Est.
$2.80
EPS Surpr.
+2.1%
Revenue
$1.43B
Q1 FY2026
Jan 29, 2026Beat
EPS Actual
$2.81
EPS Est.
$2.74
EPS Surpr.
+2.5%
Revenue
$1.42B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$2.55
EPS Est.
$2.51
EPS Surpr.
+1.6%
Revenue
$1.34B
Q3 FY2025
Jul 31, 2025
EPS Actual
$2.55
EPS Est.
$2.55
EPS Surpr.
+0.0%
Revenue
$1.35B
Q2 FY2025
Apr 23, 2025
EPS Actual
$2.37
EPS Est.
$2.38
EPS Surpr.
-0.4%
Revenue
$1.29B
Q1 FY2025
Jan 30, 2025Beat
EPS Actual
$2.43
EPS Est.
$2.32
EPS Surpr.
+4.7%
Revenue
$1.28B
Q4 FY2024
Oct 24, 2024Beat
EPS Actual
$2.20
EPS Est.
$2.04
EPS Surpr.
+7.8%
Revenue
$1.22B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $3.73 | $3.79 | $3.84 | 2 |
| Q1 FY2029 | $3.67 | $3.73 | $3.78 | 4 |
| Q4 FY2028 | $3.64 | $3.70 | $3.74 | 5 |
| Q3 FY2028 | $3.28 | $3.33 | $3.37 | 5 |
| Q2 FY2028 | $3.46 | $3.52 | $3.56 | 6 |
| Q1 FY2028 | $3.39 | $3.45 | $3.49 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $1.7B | $1.7B | $1.7B | 3 |
| Q1 FY2029 | $1.7B | $1.7B | $1.7B | 5 |
| Q4 FY2028 | $1.6B | $1.7B | $1.7B | 4 |
| Q3 FY2028 | $1.6B | $1.6B | $1.7B | 4 |
| Q2 FY2028 | $1.6B | $1.7B | $1.7B | 5 |
| Q1 FY2028 | $1.6B | $1.6B | $1.6B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +2.1% | $211.93 | $213.81 | +0.89% |
| ▲ Q1 FY2026 | Jan 29, 2026 | +2.5% | $257.72 | $257.61 | -0.04% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +1.6% | $253.62 | $252.26 | -0.54% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +0.0% | $277.44 | $271.94 | -1.98% |
| ▲ Q2 FY2025 | Apr 23, 2025 | -0.4% | $214.08 | $214.36 | +0.13% |
| ▲ Q1 FY2025 | Jan 30, 2025 | +4.7% | $252.86 | $257.65 | +1.89% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +7.8% | $237.40 | $239.05 | +0.70% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +0.5% | $213.25 | $214.56 | +0.61% |
Q2 FY2026+0.89%
Report Date
Apr 30, 2026
EPS Beat/Miss
+2.1%
Price Before
$211.93
Price After
$213.81
Q1 FY2026-0.04%
Report Date
Jan 29, 2026
EPS Beat/Miss
+2.5%
Price Before
$257.72
Price After
$257.61
Q4 FY2025-0.54%
Report Date
Oct 30, 2025
EPS Beat/Miss
+1.6%
Price Before
$253.62
Price After
$252.26
Q3 FY2025-1.98%
Report Date
Jul 31, 2025
EPS Beat/Miss
+0.0%
Price Before
$277.44
Price After
$271.94
Q2 FY2025+0.13%
Report Date
Apr 23, 2025
EPS Beat/Miss
-0.4%
Price Before
$214.08
Price After
$214.36
Q1 FY2025+1.89%
Report Date
Jan 30, 2025
EPS Beat/Miss
+4.7%
Price Before
$252.86
Price After
$257.65
Q4 FY2024+0.70%
Report Date
Oct 24, 2024
EPS Beat/Miss
+7.8%
Price Before
$237.40
Price After
$239.05
Q3 FY2024+0.61%
Report Date
Aug 1, 2024
EPS Beat/Miss
+0.5%
Price Before
$213.25
Price After
$214.56
Avg Beat Reaction+0.21%
Beat Rate8 / 8 quarters
Largest Move-1.98% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RMD ends December
ResMed Inc. (RMD) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $2.86 — beating the analyst consensus of $2.80 by +2.1%. RMD has beaten EPS estimates for 4 consecutive quarters. The next RMD earnings date is expected around September 1, 2026.
Each quarter, investors track RMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RMD earnings · 5 questionsResMed Inc.'s next earnings report is expected around September 1, 2026. RMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RMD historically reports after market close (AMC).
RMD earnings datewhen is RMD earningsRMD next earnings datewhen does RMD report earningsRMD earnings calendar
▸ Source: FMP · ResMed Inc. SEC filings · US GAAP · ResMed Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026